A phase II study of SGN-40 (anti-huCD40 mAb) in patients with relapsed diffuse large B-cell lymphoma (DLBCL)
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2015
At a glance
- Drugs Dacetuzumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Seattle Genetics
- 16 Jun 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2008 1 Dec 2008 added as the planned end date based on information from ClinicalTrials.gov.